TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q2 2023 Earnings Call Transcript

Daniel Carlson: You brought a long way in a short time, it appears. So, last question for me, Harlan. I mean, you focused rightly on the two Phase 2s, but there were a number of other potential balls out there in the air. I’m just wondering if there is anything progressing on the third party work that you’ve been working on in the past, or if that’s just sort of all silent now?

Harlan Weisman: Thank you, Dan, for that question. We still have ongoing collaborations going with some big pharma companies and also biotech companies. It is going on in the background. The one thing we have done is we have changed the emphasis of what we are doing to throw as many hooks out there to catch fish to be more focused and go to the fishing hole where the fish actually are. And so, we are saying, one, we’ve narrowed our — the focus to be only on those programs that we think we can make a real difference that our business interests to the collaborator that might lead to — where we can add value that might lead to a business deal in the future. And the other is that we want people to pay their way completely before we were doing quite a lot of work, where we were taking on the burden of the cost.

It wasn’t tremendous cost, but we were taking on that burden. Now, we want — if somebody wants to collaborate with us, and part of demonstrating that it’s important to them is for them paying their way. So, we have a more narrowed group of collaborations that we have going on. And, of course, we have the government collaborations, which we are very excited about. We’ve received that pace for our laboratory costs, our human resource is devoted to those projects. And we’re exploring other opportunities on the nondilutional side of working with government and other organizations.

Operator: Thank you. There no further questions. I will turn the call back over for closing comments.

Dr. Harlan Weisman: Well, in closing, I’d just like to thank all of you for being on today’s call. And I’d especially like to thank all of our investors who’ve demonstrated their belief in and support of our company. I’m convinced the TFF VORI and TFF TAC programs have the potential to significantly advance the current standard-of-care in their respective rare disease indication. And that’s why I, as well as our officers, directors and employees have purchased significant equity in our company. Thank you again, and we look forward to providing another corporate update in November.

Operator: Ladies and gentlemen, this concludes your conference call for today. We thank you for participating, and we ask that you please disconnect your lines.